ObesityPhase 1NCT07915245
A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy
A Phase 1 study testing LY4247147 in people with Obesity and Overweight, run by Eli Lilly and Company at 3 sites in 2 countries.
Trial summary
The main purpose of this study is to understand how safe and well-tolerated LY4247147 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4247147 gets into the bloodstream and how long it takes the body to eliminate it. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Obesity, Overweight
- What is being tested?
- LY4247147
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 108 participants
- Where
- 3 sitesin 2 countries
- Study dates
- Nov 2026to Oct 2028
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease.
- Have overweight with a BMI of greater than or equal to (≥) 27 kilograms per square meter (kg/m²).
- Have obesity with a BMI of ≥30 kg/m2.
- Have had a self-reported stable weight for 3 months prior to screening.
- Singapore only: Participants must be 21 to 65 years of age.
Who cannot join
- Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data.
- Is an individual of childbearing potential (IOCBP).
Trial locations and contacts
3 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
3 sites in 2 countries
United States2 sites
ICON Early Phase Services Lenexa Center
Lenexa, Kansas, 66219
913-410-2485
Patrick Yao
ICON
Salt Lake City, Utah, 84124
801-904-4514
Konstantin Malley
Singapore1 site
Lilly Centre for Clinical Pharmacology
Singapore, 138623
64139811
Jennifer Boon Wee
About this study
Official title: A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy
The main purpose of this study is to understand how safe and well-tolerated LY4247147 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4247147 gets into the bloodstream and how long it takes the body to eliminate it.
The study will be conducted in 3 parts. For each participant in Parts A and C, the study will last about 30 weeks and will include a stay in the Clinical Research Unit (CRU) lasting about 8 nights. For each participant in Part B, the study will last about 39 weeks and will include up to 3 stays in the CRU lasting about 9 nights each.
- Conditions
- Obesity, Overweight
- Being tested
- LY4247147, Placebo
- Medical subject headings
- Obesity, Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LY4247147Drug
administered SC
LY4247147Drug
administered IV
PlaceboDrug
administered SC
| Study group | Role | What they receive |
|---|---|---|
| LY4247147 Part A | Experimental | LY4247147 administered subcutaneously (SC) Receives: Drug: LY4247147 |
| Placebo Part A | Placebo comparator | Placebo administered SC Receives: Drug: Placebo |
| LY4247147 Part B | Experimental | LY4247147 administered SC Receives: Drug: LY4247147 |
| Placebo Part B | Placebo comparator | Placebo administered SC Receives: Drug: Placebo |
| LY4247147 Part C | Experimental | LY4247147 administered intravenously (IV) Receives: Drug: LY4247147 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Measured: Baseline through End of the Follow-up (Estimated as Week 25)
Part B: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Measured: Baseline through End of the Follow-up (Estimated as Week 33)
Secondary outcomes (6)
Part A and C: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY4247147
Measured: Predose on Day 1 through Week 25
Part B: PK: Cmax of LY4247147
Measured: Predose on Day 1 through Week 33
Part A: PK: Time of Maximum Observed Drug Concentration (Tmax) of LY4247147
Measured: Predose on Day 1 through Week 25
Part B: PK: Tmax of LY4247147
Measured: Predose on Day 1 through Week 33
Part A and C: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4247147
Measured: Predose on Day 1 through Week 25
Part B: PK: AUC of LY4247147
Measured: Predose on Day 1 through Week 33
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Nov 2026
- Study startNov 2026 (estimated)
- Primary completionOct 2028 (estimated)
- Study completionOct 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 108 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07915245
- Sponsor's protocol ID
- 27798
- Other IDs
- J6X-MC-YNAA
- Status last verified
- Oct 2026
- First submitted
- 30 Oct 2026
- Last updated
- 4 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy
- ClinicalTrials.gov ID
- NCT07915245
- Acronym / sponsor ID
- 27798
- Conditions
- Obesity, Overweight
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 108 participants (estimated)
- Lead sponsor
- Eli Lilly and CompanyIndustry (pharma, biotech, devices)
- Study start
- Nov 2026 (estimated)
- Primary completion
- Oct 2028 (estimated)
- Study completion
- Oct 2028 (estimated)
- First posted
- 4 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main purpose of this study is to understand how safe and well-tolerated LY4247147 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4247147 gets into the bloodstream and how long it takes the body to eliminate it.
The study will be conducted in 3 parts. For each participant in Parts A and C, the study will last about 30 weeks and will include a stay in the Clinical Research Unit (CRU) lasting about 8 nights. For each participant in Part B, the study will last about 39 weeks and will include up to 3 stays in the CRU lasting about 9 nights each.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| LY4247147 Part A | Experimental | Drug: LY4247147LY4247147 administered subcutaneously (SC) |
| Placebo Part A | Placebo comparator | Drug: PlaceboPlacebo administered SC |
| LY4247147 Part B | Experimental | Drug: LY4247147LY4247147 administered SC |
| Placebo Part B | Placebo comparator | Drug: PlaceboPlacebo administered SC |
| LY4247147 Part C | Experimental | Drug: LY4247147LY4247147 administered intravenously (IV) |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease.
- Have overweight with a BMI of greater than or equal to (≥) 27 kilograms per square meter (kg/m²).
- Have obesity with a BMI of ≥30 kg/m2.
- Have had a self-reported stable weight for 3 months prior to screening.
- Singapore only: Participants must be 21 to 65 years of age.
Key exclusion criteria (2 listed)
- Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data.
- Is an individual of childbearing potential (IOCBP).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LY4247147administered SC | Drug | LY4247147 Part A, LY4247147 Part B |
| LY4247147administered IV | Drug | LY4247147 Part C |
| Placeboadministered SC | Drug | Placebo Part A, Placebo Part B |
Primary outcome
Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time frame: Baseline through End of the Follow-up (Estimated as Week 25)
Part B: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time frame: Baseline through End of the Follow-up (Estimated as Week 33)
6 secondary outcomes
Part A and C: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY4247147
Time frame: Predose on Day 1 through Week 25
Part B: PK: Cmax of LY4247147
Time frame: Predose on Day 1 through Week 33
Part A: PK: Time of Maximum Observed Drug Concentration (Tmax) of LY4247147
Time frame: Predose on Day 1 through Week 25
Part B: PK: Tmax of LY4247147
Time frame: Predose on Day 1 through Week 33
Part A and C: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4247147
Time frame: Predose on Day 1 through Week 25
Part B: PK: AUC of LY4247147
Time frame: Predose on Day 1 through Week 33
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) study director
Eli Lilly and Company
3 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing LY4247147 in people with Obesity and Overweight, run by Eli Lilly and Company at 3 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States, Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or (1-317-615-4559, LillyTrials@Lilly.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration (time frame: Baseline through End of the Follow-up (Estimated as Week 25)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026.